adrenergic beta antagonists

DRUG2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

Conditions

ArrhythmiaAtrial FibrillationCardiovascular DiseasesHeart DiseasesHeart FailureHeart Failure, Congestive

Phase 3

Beta-Blocker Evaluation in Survival Trial (BEST)

CompletedNCT00000560

National Heart, Lung, and Blood Institute (NHLBI)Cardiovascular Diseases, Heart Diseases, Heart Failure +1

Start: 1994-06-30End: 1999-09-30Updated: 2016-04-14

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

CompletedNCT00000556

National Heart, Lung, and Blood Institute (NHLBI)Arrhythmia, Atrial Fibrillation, Cardiovascular Diseases +1

Start: 1995-03-31End: 2002-09-30Updated: 2016-03-25

Related Papers

Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation

Hypertension2017-10-0431 citations

Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits.

2017-08-0111 citations

Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction

Circulation Heart Failure2016-09-22118 citations

Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals

Circulation Heart Failure2014-12-0615 citations

Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.

2013-08-0140 citations